Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Raw Materials: 2021-2024

Historic Raw Materials for Apellis Pharmaceuticals (APLS) over the last 2 years, with Mar 2024 value amounting to $42.1 million.

  • Apellis Pharmaceuticals' Raw Materials rose 23.98% to $42.1 million in Q1 2024 from the same period last year, while for Mar 2024 it was $42.1 million, marking a year-over-year increase of 23.98%. This contributed to the annual value of $32.7 million for FY2023, which is 9.64% up from last year.
  • According to the latest figures from Q1 2024, Apellis Pharmaceuticals' Raw Materials is $42.1 million, which was up 28.62% from $32.7 million recorded in Q4 2023.
  • Apellis Pharmaceuticals' 5-year Raw Materials high stood at $42.1 million for Q1 2024, and its period low was $5.7 million during Q4 2021.
  • Over the past 3 years, Apellis Pharmaceuticals' median Raw Materials value was $29.8 million (recorded in 2022), while the average stood at $28.6 million.
  • Data for Apellis Pharmaceuticals' Raw Materials shows a peak YoY skyrocketed of 419.17% (in 2022) over the last 5 years.
  • Over the past 4 years, Apellis Pharmaceuticals' Raw Materials (Quarterly) stood at $5.7 million in 2021, then spiked by 419.17% to $29.8 million in 2022, then climbed by 9.64% to $32.7 million in 2023, then grew by 23.98% to $42.1 million in 2024.
  • Its Raw Materials stands at $42.1 million for Q1 2024, versus $32.7 million for Q4 2023 and $26.1 million for Q3 2023.